Gold P W, Kling M A, Khan I, Calabrese J R, Kalogeras K, Post R M, Avgerinos P C, Loriaux D L, Chrousos G P
Adv Biochem Psychopharmacol. 1987;43:183-200.
CRH is a 41 amino acid peptide first isolated from ovine and subsequently from rat and human hypothalami. We have conducted a series of clinical studies with oCRH and hCRH in volunteers and patients with various disorders of hypothalamic-pituitary-adrenal function. In volunteers, it was demonstrated that hCRH administration produced ACTH and cortisol responses which closely mimic naturalistically occurring secretory episodes. This data, as well as the demonstration that pulsatile hCRH can reestablish normal ACTH and cortisol secretion in patients with hypothalamic CRH deficiency, strongly argue that CRH is of physiological relevance to the human pituitary-adrenal axis. However, since the ACTH response to an insulin tolerance test is greater than the maximal ACTH response to CRH, other factors such as vasopressin may be relevant to stress-induced ACTH secretion in man. Following the demonstration that CRH seems to be of physiological relevance to human subjects, a CRH stimulation test was developed based on pharmacokinetic and dose response studies with oCRH and hCRH. Based on these data, which revealed that oCRH functions as a long-acting analogue of hCRH, and the demonstration that hormonal responses to CRH are greatest in the evening, patient groups with abnormalities of the hypothalamic-pituitary-adrenal axis were tested with intravenous oCRH with a dose of 1 micrograms/kg given at 2000 hours. This CRH stimulation test has proved helpful in clarifying the pathophysiology of hypercortisolism in a variety of psychiatric disorders characterized by this endocrine abnormality. Thus, blunted ACTH responses in hypercortisolemic patients with depression, anorexia nervosa, and panic anxiety disorder indicate normality of the pituitary corticotroph in these patient subgroups. These data, along with the finding that a continuous infusion of CRH to normal volunteers, reproduces the pattern and magnitude of hypercortisolism in depression and anorexia nervosa, suggest that the hypercortisolism in these disorders represents a defect at or above the hypothalamus resulting in the hypersecretion of CRH. This hypothesis is particularly intriguing in light of the demonstration that CRH administration to experimental animals produces many of the physiological and behavioral responses classically associated with depression and anorexia nervosa, including hypercortisolism, hypothalamic hypogonadism, and decreases in libido and appetite. The CRH stimulation test has also helped to resolve one of the oldest endocrinological dilemmas, namely whether the hypercortisolism of depression and Cushing's disease share a common or dissimilar pathophysiological basis.(ABSTRACT TRUNCATED AT 400 WORDS)
促肾上腺皮质激素释放激素(CRH)是一种由41个氨基酸组成的肽,最初从绵羊下丘脑分离出来,随后又从大鼠和人类下丘脑分离得到。我们对促肾上腺皮质激素释放激素(oCRH)和人促肾上腺皮质激素释放激素(hCRH)在志愿者以及患有下丘脑-垂体-肾上腺功能各种紊乱的患者中进行了一系列临床研究。在志愿者中,已证明给予hCRH会产生促肾上腺皮质激素(ACTH)和皮质醇反应,这些反应紧密模拟自然发生的分泌过程。这些数据,以及搏动性hCRH可使下丘脑CRH缺乏患者的ACTH和皮质醇分泌恢复正常的证明,有力地表明CRH与人类垂体-肾上腺轴具有生理相关性。然而,由于对胰岛素耐量试验的ACTH反应大于对CRH的最大ACTH反应,其他因素如血管加压素可能与人类应激诱导的ACTH分泌有关。在证明CRH似乎与人类受试者具有生理相关性之后,基于对oCRH和hCRH的药代动力学和剂量反应研究开发了CRH刺激试验。基于这些数据,揭示了oCRH作为hCRH的长效类似物起作用,以及证明对CRH的激素反应在晚上最大,对下丘脑-垂体-肾上腺轴异常的患者组在2000时静脉注射剂量为1微克/千克的oCRH进行测试。这种CRH刺激试验已被证明有助于阐明以这种内分泌异常为特征的各种精神疾病中皮质醇增多症的病理生理学。因此,抑郁症、神经性厌食症和惊恐焦虑症的高皮质醇血症患者中ACTH反应减弱表明这些患者亚组中垂体促肾上腺皮质细胞正常。这些数据,以及对正常志愿者持续输注CRH会重现抑郁症和神经性厌食症中皮质醇增多症的模式和程度这一发现,表明这些疾病中的皮质醇增多症代表下丘脑或其上方的缺陷,导致CRH分泌过多。鉴于对实验动物给予CRH会产生许多经典上与抑郁症和神经性厌食症相关的生理和行为反应,包括皮质醇增多症、下丘脑性腺功能减退以及性欲和食欲下降,这一假设特别引人关注。CRH刺激试验也有助于解决最古老的内分泌难题之一,即抑郁症和库欣病的皮质醇增多症是否有共同或不同的病理生理基础。(摘要截短为400字)